Form 4: Soleno Therapeutics CFO James H. Mackaness Sells Shares to Cover Tax Obligations

James H. Mackaness, CFO of Soleno Therapeutics Inc., sold shares of common stock on July 1, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On July 1, 2024, James H. Mackaness, the Chief Financial Officer of Soleno Therapeutics Inc., executed two transactions involving the sale of common stock.
• The first transaction involved the sale of 1,568 shares at a weighted average price of $41.2217, with prices ranging from $40.39 to $41.38.
• The second transaction involved the sale of 5,622 shares at a weighted average price of $41.6254, with prices ranging from $41.39 to $42.08.
• These sales were conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following these transactions, Mackaness directly owns 55,763 shares of Soleno Therapeutics Inc.
• Certain of these securities are RSUs, each representing a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports the sale of shares to cover tax obligations, which is a routine transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO in this case, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The sale of shares by a company insider could be perceived negatively by some shareholders, but the explanation provided (covering tax obligations) mitigates this concern.

Key Dates